An Overview of the Biological Processes of Mesenchymal Stem Cells and Their Response to an Inflammatory Milieu
DOI:
https://doi.org/10.13052/ijts2246-8765.2025.003Keywords:
Stem cells, cytokines, inflammation, NFκB, purinergic receptors, multipotencyAbstract
There is continued interest in applying adult human mesenchymal stem cells (MSCs) in tissue regeneration, as well as mitigating overt inflammation such as graft versus host disease. MSCs are derived from different sources such as bone marrow, bone chips, dental pulp, adipose tissues, and placenta. MSCs appear to exert a memory for their tissue of origin. Interestingly, despite positive outcomes of MSCs in vivo, their survival in host tissues appears to be short-lived. To date, based on research and clinical literature, there is a need to understand how MSCs are maintained in a multipotent state. We discuss the role for the inflammatory milieu in which soluble and insoluble such as exosomes can determine the immune response of MSCs – suppressor versus enhancer. This article discusses a central role for the transcription factor NFκB in maintaining multipotency, and discusses how the inflammatory milieu influences the differentiation of MSCs. Lessons are drawn from the literature on MSCs in cancer to further describe the role of NFκB in maintaining the stem cell state. The findings outlined in this article could be important to future translational studies.
Downloads
References
Sherman, L. S., A. Condé-Green, O. A. Sandiford, and P. Rameshwar. 2015. A discussion on adult mesenchymal stem cells for drug delivery: pros and cons. Ther Deliv 6: 1335–1346.
Sherman, L. S., M. Shaker, V. Mariotti, and P. Rameshwar. 2017. Mesenchymal stromal/stem cells in drug therapy: New perspective. Cytotherapy 19: 19–27.
Maldonado, V. V., N. H. Patel, E. E. Smith, C. L. Barnes, M. P. Gustafson, R. R. Rao, and R. M. Samsonraj. 2023. Clinical utility of mesenchymal stem/stromal cells in regenerative medicine and cellular therapy. J Biol Eng 17: 44.
Torrecillas-Baena, B., V. Pulido-Escribano, G. Dorado, M. Gálvez-Moreno, M. Camacho-Cardenosa, and A. Casado-Díaz. 2023. Clinical Potential of Mesenchymal Stem Cell-Derived Exosomes in Bone Regeneration. J Clin Med 12.
Campagnoli, C., I. A. Roberts, S. Kumar, P. R. Bennett, I. Bellantuono, and N. M. Fisk. 2001. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood 98: 2396–2402.
Castillo, M., K. Liu, L. Bonilla, and P. Rameshwar. 2007. The immune properties of mesenchymal stem cells. Int J Biomed Sci 3: 76–80.
Caplan, A. I., and S. P. Bruder. 2001. Mesenchymal stem cells: building blocks for molecular medicine in the 21st century. Trends Mol Med 7: 259–264.
Friedenstein, A. J., K. V. Petrakova, A. I. Kurolesova, and G. P. Frolova. 1968. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 6: 230–247.
Friedenstein, A. J., S. Piatetzky, II, and K. V. Petrakova. 1966. Osteogenesis in transplants of bone marrow cells. J Embryol Exp Morphol 16: 381–390.
Dominici, M., K. Le Blanc, I. Mueller, I. Slaper-Cortenbach, F. Marini, D. Krause, R. Deans, A. Keating, D. Prockop, and E. Horwitz. 2006. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8: 315–317.
Le Blanc, K., C. Tammik, K. Rosendahl, E. Zetterberg, and O. Ringdén. 2003. HLA expression and immunologic propertiesof differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 31: 890–896.
Greco, S. J., C. Zhou, J. H. Ye, and P. Rameshwar. 2007. An interdisciplinary approach and characterization of neuronal cells transdifferentiated from human mesenchymal stem cells. Stem Cells Dev 16: 811–826.
Trzaska, K. A., and P. Rameshwar. 2011. Dopaminergic neuronal differentiation protocol for human mesenchymal stem cells. Methods Mol Biol 698: 295–303.
Potian, J. A., H. Aviv, N. M. Ponzio, J. S. Harrison, and P. Rameshwar. 2003. Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J Immunol 171: 3426–3434.
Patel, S. A., L. Sherman, J. Munoz, and P. Rameshwar. 2008. Immunological properties of mesenchymal stem cells and clinical implications. Arch Immunol Ther Exp (Warsz) 56: 1–8.
Stagg, J., and J. Galipeau. 2013. Mechanisms of immune modulation by mesenchymal stromal cells and clinical translation. Curr Mol Med 13: 856–867.
Sasse, S., A. Skorska, C. A. Lux, G. Steinhoff, R. David, and R. Gaebel. 2019. Angiogenic Potential of Bone Marrow Derived CD133(+) and CD271(+) Intramyocardial Stem Cell Trans- Plantation Post MI. Cells 9: 78.
Conaty, P., L. S. Sherman, Y. Naaldijk, H. Ulrich, A. Stolzing, and P. Rameshwar. 2018. Methods of Mesenchymal Stem Cell Homing to the Blood-Brain Barrier. Methods Mol Biol 1842: 81–91.
Sandiford, O. A., R. J. Donnelly, M. H. El-Far, L. M. Burgmeyer, G. Sinha, S. H. Pamarthi, L. S. Sherman, A. I. Ferrer, D. E. DeVore, S. A. Patel, Y. Naaldijk, S. Alonso, P. Barak, M. Bryan, N. M. Ponzio, R. Narayanan, J. P. Etchegaray, R. Kumar, and P. Rameshwar. 2021. Mesenchymal Stem Cell-Secreted Extracellular Vesicles Instruct Stepwise Dedifferentiation of Breast Cancer Cells into Dormancy at the Bone Marrow Perivascular Region. Cancer Res 81: 1567–1582.
Mohamed-Ahmed, S., I. Fristad, S. A. Lie, S. Suliman, K. Mustafa, H. Vindenes, and S. B. Idris. 2018. Adipose-derived and bone marrow mesenchymal stem cells: a donor-matched comparison. Stem Cell Res Ther 9: 168.
Romagano, M. P., L. S. Sherman, B. Shadpoor, M. El-Far, S. Souayah, S. H. Pamarthi, J. Kra, A. Hood-Nehra, J. P. Etchegaray, S. F. Williams, and P. Rameshwar. 2022. Aspirin-Mediated Reset of Preeclamptic Placental Stem Cell Transcriptome – Implication for Stabilized Placental Function. Stem Cell Rev Rep 18: 3066–3082.
Sherman, L. S., A. Condé-Green, Y. Naaldijk, E. S. Lee, and P. Rameshwar. 2019. An Enzyme-free Method for Isolation and Expansion of Human Adipose-derived Mesenchymal Stem Cells. J Vis Exp. 154: e59419.
Jung, W. Y., J. H. Kang, K. G. Kim, H. S. Kim, B. I. Jang, Y. H. Park, and I. H. Song. 2015. Human adipose-derived stem cells attenuate inflammatory bowel disease in IL-10 knockout mice. Tissue Cell 47: 86–93.
Kim, Y. S., J. Y. Kim, D. M. Shin, J. W. Huh, S. W. Lee, and Y. M. Oh. 2014. Tracking intravenous adipose-derived mesenchymal stem cells in a model of elastase-induced emphysema. Tuberc Respir Dis (Seoul) 77: 116–123.
Le Blanc, K., C. Tammik, K. Rosendahl, E. Zetterberg, and O. Ringdén. 2003. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 31: 890–896.
Sherman, L. S., J. Munoz, S. A. Patel, M. A. Dave, I. Paige, and P. Rameshwar. 2011. Moving from the laboratory bench to patients’ bedside: considerations for effective therapy with stem cells. Clin Transl Sci 4: 380–386.
Ponte, A. L., E. Marais, N. Gallay, A. Langonné, B. Delorme, O. Hérault, P. Charbord, and J. Domenech. 2007. The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells 25: 1737–1745.
Honczarenko, M., Y. Le, M. Swierkowski, I. Ghiran, A. M. Glodek, and L. E. Silberstein. 2006. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells 24: 1030–1041.
Wynn, R. F., C. A. Hart, C. Corradi-Perini, L. O’Neill, C. A. Evans, J. E. Wraith, L. J. Fairbairn, and I. Bellantuono. 2004. A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood 104: 2643–2645.
Vanden Berg-Foels, W. S. 2014. In situ tissue regeneration: chemoattractants for endogenous stem cell recruitment. Tissue Eng Part B Rev 20: 28–39.
Hocking, A. M. 2015. The Role of Chemokines in Mesenchymal Stem Cell Homing to Wounds. Adv Wound Care (New Rochelle) 4: 623–630.
Kim, I., H. Park, I. Hwang, D. Moon, H. Yun, E. J. Lee, and H. S. Kim. 2021. Discovery of chemerin as the new chemoattractant of human mesenchymal stem cells. Cell Biosci 11: 120.
Cornelissen, A. S., M. W. Maijenburg, M. A. Nolte, and C. Voermans. 2015. Organ-specific migration of mesenchymal stromal cells: Who, when, where and why? Immunol Lett 168: 159–169.
Iso, Y., J. L. Spees, C. Serrano, B. Bakondi, R. Pochampally, Y. H. Song, B. E. Sobel, P. Delafontaine, and D. J. Prockop. 2007. Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftment. Biochem Biophys Res Commun 354: 700–706.
Liesveld, J. L., N. Sharma, and O. S. Aljitawi. 2020. Stem cell homing: From physiology to therapeutics. Stem Cells 38: 1241–1253.
Braid, L. R., C. A. Wood, D. M. Wiese, and B. N. Ford. 2018. Intramuscular administration potentiates extended dwell time of mesenchymal stromal cells compared to other routes. Cytotherapy 20: 232–244.
Naderi-Meshkin, H., A. R. Bahrami, H. R. Bidkhori, M. Mirahmadi, and N. Ahmadiankia. 2015. Strategies to improve homing of mesenchymal stem cells for greater efficacy in stem cell therapy. Cell Biol Intl 39: 23–34.
Lee, R. H., A. A. Pulin, M. J. Seo, D. J. Kota, J. Ylostalo, B. L. Larson, L. Semprun-Prieto, P. Delafontaine, and D. J. Prockop. 2009. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 5: 54–63.
Ren, G., X. Zhao, L. Zhang, J. Zhang, A. L’Huillier, W. Ling, A. I. Roberts, A. D. Le, S. Shi, C. Shao, and Y. Shi. 2010. Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J Immunol 184: 2321–2328.
Sherman, L. S., M. P. Romagano, S. F. Williams, and P. Rameshwar. 2019. Mesenchymal stem cell therapies in brain disease. Semin Cell Dev Biol 95: 111–119.
Soukup, R., I. Gerner, T. Mohr, S. Gueltekin, J. Grillari, and F. Jenner. 2023. Mesenchymal Stem Cell Conditioned Medium Modulates Inflammation in Tenocytes: Complete Conditioned Medium Has Superior Therapeutic Efficacy than Its Extracellular Vesicle Fraction. Int J Mol Sci 24.
Lubis, A. M. T., P. Aprianto, J. A. Pawitan, B. P. Priosoeryanto, T. I. T. Dewi, and A. F. Kamal. 2023. Intra-articular injection of secretome, derived from umbilical cord mesenchymal stem cell, enhances the regeneration process of cartilage in early-stage osteo-arthritis: an animal study. Acta Orthop 94: 300–306.
Fischer, U. M., M. T. Harting, F. Jimenez, W. O. Monzon-Posadas, H. Xue, S. I. Savitz, G. A. Laine, and C. S. Cox, Jr. 2009. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev 18: 683–692.
Kerkelä, E., T. Hakkarainen, T. Mäkelä, M. Raki, O. Kambur, L. Kilpinen, J. Nikkilä, S. Lehtonen, I. Ritamo, R. Pernu, M. Pietilä, R. Takalo, T. Juvonen, K. Bergström, E. Kalso, L. Valmu, S. Laitinen, P. Lehenkari, and J. Nystedt. 2013. Transient proteolytic modification of mesenchymal stromal cells increases lung clearance rate and targeting to injured tissue. Stem Cells Transl Med 2: 510–520.
Moeinabadi-Bidgoli, K., R. Mazloomnejad, A. Beheshti Maal, H. Asadzadeh Aghdaei, M. Kazem Arki, N. Hossein-Khannazer, and M. Vosough. 2023. Genetic modification and preconditioning strategies to enhance functionality of mesenchymal stromal cells: a clinical perspective. Expert Opin Biol Ther 23: 461–478.
Kim, D. S., J. H. Kim, J. K. Lee, S. J. Choi, J. S. Kim, S. S. Jeun, W. Oh, Y. S. Yang, and J. W. Chang. 2009. Overexpression of CXC chemokine receptors is required for the superior glioma-tracking property of umbilical cord blood-derived mesenchymal stem cells. Stem Cells Dev 18: 511–519.
Haider, H., S. Jiang, N. M. Idris, and M. Ashraf. 2008. IGF-1-overexpressing mesenchymal stem cells accelerate bone marrow stem cell mobilization via paracrine activation of SDF-1alpha/CXCR4 signaling to promote myocardial repair. Circ Res 103: 1300–1308.
Huang, B., J. Qian, J. Ma, Z. Huang, Y. Shen, X. Chen, A. Sun, J. Ge, and H. Chen. 2014. Myocardial transfection of hypoxia-inducible factor-1α
and co-transplantation of mesenchymal stem cells enhance cardiac repair in rats with experimental myocardial infarction. Stem Cell Res Ther 5: 22.
Vittorio, O., P. Quaranta, V. Raffa, N. Funel, D. Campani, S. Pelliccioni, B. Longoni, F. Mosca, A. Pietrabissa, and A. Cuschieri. 2011. Magnetic carbon nanotubes: a new tool for shepherding mesenchymal stem cells by magnetic fields. Nanomedicine 6: 43–54.
Doyle, L. M., and M. Z. Wang. 2019. Overview of Extracellular Vesicles, Their Origin, Composition, Purpose, and Methods for Exosome Isolation and Analysis. Cells 8: 727.
Zhou, H., T. Pisitkun, A. Aponte, P. S. Yuen, J. D. Hoffert, H. Yasuda, X. Hu, L. Chawla, R. F. Shen, M. A. Knepper, and R. A. Star. 2006. Exosomal Fetuin-A identified by proteomics: a novel urinary biomarker for detecting acute kidney injury. Kidney Int 70: 1847–1857.
Sandfeld-Paulsen, B., N. Aggerholm-Pedersen, R. Bæk, K. R. Jakobsen, P. Meldgaard, B. H. Folkersen, T. R. Rasmussen, K. Varming, M. M. Jørgensen, and B. S. Sorensen. 2016. Exosomal proteins as prognostic biomarkers in non-small cell lung cancer. Mol Oncol 10: 1595–1602.
Simpson, R. J., J. W. Lim, R. L. Moritz, and S. Mathivanan. 2009. Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteomics 6: 267–283.
Deng, H., C. Sun, Y. Sun, H. Li, L. Yang, D. Wu, Q. Gao, and X. Jiang. 2018. Lipid, Protein, and MicroRNA Composition Within Mesenchymal Stem Cell-Derived Exosomes. Cell Reprogram 20: 178–186.
Harrell, C. R., N. Jovicic, V. Djonov, and V. Volarevic. 2020. Therapeutic Use of Mesenchymal Stem Cell-Derived Exosomes: From Basic Science to Clinics. Pharmaceutics 12: 474.
Lee, B. C., I. Kang, and K. R. Yu. 2021. Therapeutic Features and Updated Clinical Trials of Mesenchymal Stem Cell (MSC)-Derived Exosomes. J Clin Med 10.
Reis, L. A., F. T. Borges, M. J. Simões, A. A. Borges, R. Sinigaglia-Coimbra, and N. Schor. 2012. Bone marrow-derived mesenchymal stem cells repaired but did not prevent gentamicin-induced acute kidney injury through paracrine effects in rats. PLoS One 7: e44092.
Gatti, S., S. Bruno, M. C. Deregibus, A. Sordi, V. Cantaluppi, C. Tetta, and G. Camussi. 2011. Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. Nephrol Dial Transplant 26: 1474–1483.
Allahdadi, K. J., T. A. de Santana, G. C. Santos, C. M. Azevedo, R. A. Mota, C. K. Nonaka, D. N. Silva, C. X. R. Valim, C. P. Figueira, W. L. C. Dos Santos, R. F. do Espirito Santo, A. F. Evangelista, C. F. Villarreal, R. R. Dos Santos, B. S. F. de Souza, and M. B. P. Soares. 2019. IGF-1 overexpression improves mesenchymal stem cell survival and promotes neurological recovery after spinal cord injury. Stem Cell Res Ther 10: 146.
Ren, S., Y. Lin, W. Liu, L. Yang, and M. Zhao. 2023. MSC-Exos: Important active factor of bone regeneration. Front Bioeng Biotechnol 11: 1136453.
Willis, G. R., A. Fernandez-Gonzalez, J. Anastas, S. H. Vitali, X. Liu, M. Ericsson, A. Kwong, S. A. Mitsialis, and S. Kourembanas. 2018. Mesenchymal Stromal Cell Exosomes Ameliorate Experimental Bronchopulmonary Dysplasia and Restore Lung Function through Macrophage Immunomodulation. Am J Respir Crit Care Med 197: 104–116.
Sotiropoulou, P. A., S. A. Perez, A. D. Gritzapis, C. N. Baxevanis, and M. Papamichail. 2006. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 24: 74–85.
He, X., Z. Dong, Y. Cao, H. Wang, S. Liu, L. Liao, Y. Jin, L. Yuan, and B. Li. 2019. MSC-Derived Exosome Promotes M2 Polarization and Enhances Cutaneous Wound Healing. Stem Cells Int 2019: 7132708.
Liang, X., L. Zhang, S. Wang, Q. Han, and R. C. Zhao. 2016. Exosomes secreted by mesenchymal stem cells promote endothelial cell angiogenesis by transferring miR-125a. J Cell Sci 129: 2182–2189.
Jia, Y., S. Qiu, J. Xu, Q. Kang, and Y. Chai. 2020. Exosomes Secreted by Young Mesenchymal Stem Cells Promote New Bone Formation During Distraction Osteogenesis in Older Rats. Calcif Tissue Int 106: 509–517.
Zhang, S., S. J. Chuah, R. C. Lai, J. H. P. Hui, S. K. Lim, and W. S. Toh. 2018. MSC exosomes mediate cartilage repair by enhancing proliferation, attenuating apoptosis and modulating immune reactivity. Biomaterials 156: 16–27.
Arslan, F., R. C. Lai, M. B. Smeets, L. Akeroyd, A. Choo, E. N. Aguor, L. Timmers, H. V. van Rijen, P. A. Doevendans, G. Pasterkamp, S. K. Lim, and D. P. de Kleijn. 2013. Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury. Stem Cell Res 10: 301–312.
Lim, P. K., S. A. Bliss, S. A. Patel, M. Taborga, M. A. Dave, L. A. Gregory, S. J. Greco, M. Bryan, P. S. Patel, and P. Rameshwar. 2011. Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells. Cancer Res 71: 1550–1560.
Chen, J., C. Li, and L. Chen. 2015. The Role of Microvesicles Derived from Mesenchymal Stem Cells in Lung Diseases. Biomed Res Int 2015: 985814.
Bliss, S. A., G. Sinha, O. A. Sandiford, L. M. Williams, D. J. Engelberth, K. Guiro, L. L. Isenalumhe, S. J. Greco, S. Ayer, and M. Bryan. 2016. Mesenchymal stem cell–derived exosomes stimulate cycling quiescence and early breast cancer dormancy in bone marrow. Cancer Res 76: 5832–5844.
Valadi, H., K. Ekström, A. Bossios, M. Sjöstrand, J. J. Lee, and J. O. Lötvall. 2007. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9: 654–659.
Kang, H. S., M. Habib, J. Chan, C. Abavana, J. A. Potian, N. M. Ponzio, and P. Rameshwar. 2005. A paradoxical role for IFN-gamma in the immune properties of mesenchymal stem cells during viral challenge. Exp Hematol 33: 796–803.
Aggarwal, S., and M. F. Pittenger. 2005. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105: 1815–1822.
Ren, G., L. Zhang, X. Zhao, G. Xu, Y. Zhang, A. I. Roberts, R. C. Zhao, and Y. Shi. 2008. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2: 141–150.
Valencic, E., C. Loganes, S. Cesana, E. Piscianz, G. Gaipa, E. Biagi, and A. Tommasini. 2014. Inhibition of mesenchymal stromal cells by pre-activated lymphocytes and their culture media. Stem Cell Res Ther 5: 3.
Di Nicola, M., C. Carlo-Stella, M. Magni, M. Milanesi, P. D. Longoni, P. Matteucci, S. Grisanti, and A. M. Gianni. 2002. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99: 3838–3843.
Li, Y. P., S. Paczesny, E. Lauret, S. Poirault, P. Bordigoni, F. Mekhloufi, O. Hequet, Y. Bertrand, J. P. Ou-Yang, J. F. Stoltz, P. Miossec, and A. Eljaafari. 2008. Human mesenchymal stem cells license adult CD34+ hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the Notch pathway. J Immunol 180: 1598–1608.
Uccelli, A., L. Moretta, and V. Pistoia. 2008. Mesenchymal stem cells in health and disease. Nature Reviews Immunology 8: 726–736.
Jiang, X. X., Y. Zhang, B. Liu, S. X. Zhang, Y. Wu, X. D. Yu, and N. Mao. 2005. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 105: 4120–4126.
Aiello, A., F. Farzaneh, G. Candore, C. Caruso, S. Davinelli, C. M. Gambino, M. E. Ligotti, N. Zareian, and G. Accardi. 2019. Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention. Front Immunol 10: 2247.
Spaggiari, G. M., A. Capobianco, S. Becchetti, M. C. Mingari, and L. Moretta. 2006. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 107: 1484–1490.
Bai, L., D. P. Lennon, V. Eaton, K. Maier, A. I. Caplan, S. D. Miller, and R. H. Miller. 2009. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia 57: 1192–1203.
Luz-Crawford, P., F. Djouad, K. Toupet, C. Bony, M. Franquesa, M. J. Hoogduijn, C. Jorgensen, and D. Noël. 2016. Mesenchymal Stem Cell-Derived Interleukin 1 Receptor Antagonist Promotes Macrophage Polarization and Inhibits B Cell Differentiation. Stem Cells 34: 483–492.
Lu, D., X. Jiao, W. Jiang, L. Yang, Q. Gong, X. Wang, M. Wei, and S. Gong. 2023. Mesenchymal stem cells influence monocyte/macrophage phenotype: Regulatory mode and potential clinical applications. Biomed Pharmacother 165: 115042.
Bozorgmehr, M., S. Gurung, S. Darzi, S. Nikoo, S. Kazemnejad, A. H. Zarnani, and C. E. Gargett. 2020. Endometrial and Menstrual Blood Mesenchymal Stem/Stromal Cells: Biological Properties and Clinical Application. Front Cell Dev Biol 8: 497.
Salamonsen, L. A., J. C. Hutchison, and C. E. Gargett. 2021. Cyclical endometrial repair and regeneration. Development 148: dev199577.
Gjorgieva, D., N. Zaidman, and D. Bosnakovski. 2013. Mesenchymal stem cells for anti-cancer drug delivery. Recent Pat Anticancer Drug Discov 8: 310–318.
Wang, X., H. Jiang, L. Guo, S. Wang, W. Cheng, L. Wan, Z. Zhang, L. Xing, Q. Zhou, X. Yang, H. Han, X. Chen, and X. Wu. 2021. SDF-1 secreted by mesenchymal stem cells promotes the migration of endothelial progenitor cells via CXCR4/PI3K/AKT pathway. J Mol Histol 52: 1155–1164.
Niu, J., W. Yue, Z. Le-Le, L. Bin, and X. Hu. 2017. Mesenchymal stem cells inhibit T cell activation by releasing TGF-β
from TGF-β
/GARP complex. Oncotarget 8: 99784–99800.
Shigemoto-Kuroda, T., J. Y. Oh, D. K. Kim, H. J. Jeong, S. Y. Park, H. J. Lee, J. W. Park, T. W. Kim, S. Y. An, D. J. Prockop, and R. H. Lee. 2017. MSC-derived Extracellular Vesicles Attenuate Immune Responses in Two Autoimmune Murine Models: Type 1 Diabetes and Uveoretinitis. Stem Cell Reports 8: 1214–1225.
Greco, S. J., and P. Rameshwar. 2012. Mesenchymal stem cells in drug/gene delivery: implications for cell therapy. Ther Deliv 3: 997–1004.
Munoz, J. L., S. A. Bliss, S. J. Greco, S. H. Ramkissoon, K. L. Ligon, and P. Rameshwar. 2013. Delivery of Functional Anti-miR-9 by Mesenchymal Stem Cell-derived Exosomes to Glioblastoma Multiforme Cells Conferred Chemosensitivity. Mol Ther Nucleic Acids 2: e126.
Shah, K. 2012. Mesenchymal stem cells engineered for cancer therapy. Adv Drug Deliv Rev 64: 739–748.
Lin, P., Y. Lin, D. P. Lennon, D. Correa, M. Schluchter, and A. I. Caplan. 2012. Efficient lentiviral transduction of human mesenchymal stem cells that preserves proliferation and differentiation capabilities. Stem Cells Transl Med 1: 886–897.
Loebinger, M. R., A. Eddaoudi, D. Davies, and S. M. Janes. 2009. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res 69: 4134–4142.
Rohban, R., and T. R. Pieber. 2017. Mesenchymal Stem and Progenitor Cells in Regeneration: Tissue Specificity and Regenerative Potential. Stem Cells Int 2017: 5173732.
Cho, K. J., K. A. Trzaska, S. J. Greco, J. McArdle, F. S. Wang, J. H. Ye, and P. Rameshwar. 2005. Neurons derived from human mesenchymal stem cells show synaptic transmission and can be induced to produce the neurotransmitter substance P by interleukin-1 alpha. Stem Cells 23: 383–391.
Torper, O., U. Pfisterer, D. A. Wolf, M. Pereira, S. Lau, J. Jakobsson, A. Björklund, S. Grealish, and M. Parmar. 2013. Generation of induced neurons via direct conversion in vivo. Proc Natl Acad Sci U S A 110: 7038–7043.
Liu, T., L. Zhang, D. Joo, and S. C. Sun. 2017. NF-κ
B signaling in inflammation. Signal Transduct Target Ther 2: 1–9.
Oeckinghaus, A., and S. Ghosh. 2009. The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol 1: a000034.
Sun, S. C., J. H. Chang, and J. Jin. 2013. Regulation of nuclear factor-κ
B in autoimmunity. Trends Immunol 34: 282–289.
Linnell, J., R. Mott, S. Field, D. P. Kwiatkowski, J. Ragoussis, and I. A. Udalova. 2004. Quantitative high-throughput analysis of transcription factor binding specificities. Nucleic Acids Res 32: e44.
Chen, F. E., D. B. Huang, Y. Q. Chen, and G. Ghosh. 1998. Crystal structure of p50/p65 heterodimer of transcription factor NF-kappaB bound to DNA. Nature 391: 410–413.
Wong, D., A. Teixeira, S. Oikonomopoulos, P. Humburg, I. N. Lone, D. Saliba, T. Siggers, M. Bulyk, D. Angelov, S. Dimitrov, I. A. Udalova, and J. Ragoussis. 2011. Extensive characterization of NF-kappaB binding uncovers non-canonical motifs and advances the interpretation of genetic functional traits. Genome Biol 12: R70.
Sun, S. C. 2011. Non-canonical NF-κ
B signaling pathway. Cell Res 21: 71–85.
Beinke, S., and S. C. Ley. 2004. Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology. Biochem J 382: 393–409.
Hoesel, B., and J. A. Schmid. 2013. The complexity of NF-kappaB signaling in inflammation and cancer. Mol Cancer 12: 86.
Hatada, E. N., A. Nieters, F. G. Wulczyn, M. Naumann, R. Meyer, G. Nucifora, T. W. McKeithan, and C. Scheidereit. 1992. The ankyrin repeat domains of the NF-kappa B precursor p105 and the protooncogene bcl-3 act as specific inhibitors of NF-kappa B DNA binding. Proc Natl Acad Sci U S A 89: 2489–2493.
Sun, S. C., P. A. Ganchi, D. W. Ballard, and W. C. Greene. 1993. NF-kappa B controls expression of inhibitor I kappa B alpha: evidence for an inducible autoregulatory pathway. Science 259: 1912–1915.
Scott, M. L., T. Fujita, H. C. Liou, G. P. Nolan, and D. Baltimore. 1993. The p65 subunit of NF-kappa B regulates I kappa B by two distinct mechanisms. Genes Dev 7: 1266–1276.
Zhang, H., and S. C. Sun. 2015. NF-κ
B in inflammation and renal diseases. Cell Biosci 5: 63.
Zuckerman, S. H., G. F. Evans, and L. Guthrie. 1991. Transcriptional and post-transcriptional mechanisms involved in the differential expression of LPS-induced IL-1 and TNF mRNA. Immunol 73: 460–465.
Foxwell, B. M., J. Bondeson, F. Brennan, and M. Feldmann. 2000. Adenoviral transgene delivery provides an approach to identifying important molecular processes in inflammation: evidence for heterogenecity in the requirement for NFkappaB in tumour necrosis factor production. Ann Rheum Dis 59 Suppl 1: i54–59.
Johnson, D. R., I. Douglas, A. Jahnke, S. Ghosh, and J. S. Pober. 1996. A sustained reduction in IkappaB-beta may contribute to persistent NF-kappaB activation in human endothelial cells. J Biol Chem 271: 16317–16322.
Karin, M., and M. Delhase. 2000. The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling. Semin Immunol 12: 85–98.
Hayden, M. S., and S. Ghosh. 2008. Shared principles in NF-kappaB signaling. Cell 132: 344–362.
Sun, S. C., and S. C. Ley. 2008. New insights into NF-kappaB regulation and function. Trends Immunol 29: 469–478.
Israël, A. 2010. The IKK complex, a central regulator of NF-kappaB activation. Cold Spring Harb Perspect Biol 2: a000158.
O’Mahony, A., X. Lin, R. Geleziunas, and W. C. Greene. 2000. Activation of the heterodimeric IkappaB kinase alpha (IKKalpha)-IKKbeta complex is directional: IKKalpha regulates IKKbeta under both basal and stimulated conditions. Mol Cell Biol 20: 1170–1178.
Sun, S. C., and Z. G. Liu. 2011. A special issue on NF-κ
B signaling and function. Cell Res 21: 1–2.
Sun, S. C. 2012. The noncanonical NF-κ
B pathway. Immunol Rev 246: 125–140.
Lawrence, T. 2009. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol 1: a001651.
Sun, S. C. 2011. Non-canonical NF-kappaB signaling pathway. Cell Res 21: 71–85.
Senftleben, U., Y. Cao, G. Xiao, F. R. Greten, G. Krähn, G. Bonizzi, Y. Chen, Y. Hu, A. Fong, S. C. Sun, and M. Karin. 2001. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 293: 1495–1499.
Bonizzi, G., M. Bebien, D. C. Otero, K. E. Johnson-Vroom, Y. Cao, D. Vu, A. G. Jegga, B. J. Aronow, G. Ghosh, R. C. Rickert, and M. Karin. 2004. Activation of IKKalpha target genes depends on recognition of specific kappaB binding sites by RelB:p52 dimers. EMBO J 23: 4202–4210.
Xiao, G., E. W. Harhaj, and S. C. Sun. 2001. NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Mol Cell 7: 401–409.
Tak, P. P., and G. S. Firestein. 2001. NF-kappaB: a key role in inflammatory diseases. J Clin Invest 107: 7–11.
Sutterwala, F. S., S. Haasken, and S. L. Cassel. 2014. Mechanism of NLRP3 inflammasome activation. Ann N Y Acad Sci 1319: 82–95.
Sica, A., T. H. Tan, N. Rice, M. Kretzschmar, P. Ghosh, and H. A. Young. 1992. The c-rel protooncogene product c-Rel but not NF-kappa B binds to the intronic region of the human interferon-gamma gene at a site related to an interferon-stimulable response element. Proc Natl Acad Sci U S A 89: 1740–1744.
Mori, N., and D. Prager. 1996. Transactivation of the interleukin-1alpha promoter by human T-cell leukemia virus type I and type II Tax proteins. Blood 87: 3410–3417.
Hiscott, J., J. Marois, J. Garoufalis, M. D’Addario, A. Roulston, I. Kwan, N. Pepin, J. Lacoste, H. Nguyen, G. Bensi, and et al. 1993. Characterization of a functional NF-kappa B site in the human interleukin 1 beta promoter: evidence for a positive autoregulatory loop. Mol Cell Biol 13: 6231–6240.
Xu, L. G., and H. B. Shu. 2002. TNFR-associated factor-3 is associated with BAFF-R and negatively regulates BAFF-R-mediated NF-kappa B activation and IL-10 production. J Immunol 169: 6883–6889.
Collart, M. A., P. Baeuerle, and P. Vassalli. 1990. Regulation of tumor necrosis factor alpha transcription in macrophages: involvement of four kappa B-like motifs and of constitutive and inducible forms of NF-kappa B. Mol Cell Biol 10: 1498–1506.
Messer, G., E. H. Weiss, and P. A. Baeuerle. 1990. Tumor necrosis factor beta (TNF-beta) induces binding of the NF-kappa B transcription factor to a high-affinity kappa B element in the TNF-beta promoter. Cytokine 2: 389–397.
Smale, S. T. 2011. Hierarchies of NF-kappaB target-gene regulation. Nat Immunol 12: 689–694.
Collins, T., M. A. Read, A. S. Neish, M. Z. Whitley, D. Thanos, and T. Maniatis. 1995. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J 9: 899–909.
Duckett, C. S. 2002. Apoptosis and NF-kappa B: the FADD connection. J Clin Invest 109: 579–580.
Guttridge, D. C., C. Albanese, J. Y. Reuther, R. G. Pestell, and A. S. Baldwin, Jr. 1999. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 19: 5785–5799.
La Rosa, F. A., J. W. Pierce, and G. E. Sonenshein. 1994. Differential regulation of the c-myc oncogene promoter by the NF-kappa B rel family of transcription factors. Mol Cell Biol 14: 1039–1044.
Nickols, J. C., W. Valentine, S. Kanwal, and B. D. Carter. 2003. Activation of the transcription factor NF-kappaB in Schwann cells is required for peripheral myelin formation. Nat Neurosci 6: 161–167.
Snapper, C. M., P. Zelazowski, F. R. Rosas, M. R. Kehry, M. Tian, D. Baltimore, and W. C. Sha. 1996. B cells from p50/NF-kappa B knockout mice have selective defects in proliferation, differentiation, germ-line CH transcription, and Ig class switching. J Immunol 156: 183–191.
Neurath, M. F., S. Pettersson, K. H. Meyer zum Buschenfelde, and W. Strober. 1996. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med 2: 998–1004.
Nenci, A., C. Becker, A. Wullaert, R. Gareus, G. van Loo, S. Danese, M. Huth, A. Nikolaev, C. Neufert, B. Madison, D. Gumucio, M. F. Neurath, and M. Pasparakis. 2007. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 446: 557–561.
Greten, F. R., M. C. Arkan, J. Bollrath, L. C. Hsu, J. Goode, C. Miething, S. I. Goktuna, M. Neuenhahn, J. Fierer, S. Paxian, N. Van Rooijen, Y. Xu, T. O’Cain, B. B. Jaffee, D. H. Busch, J. Duyster, R. M. Schmid, L. Eckmann, and M. Karin. 2007. NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell 130: 918–931.
Bruey, J. M., N. Bruey-Sedano, F. Luciano, D. Zhai, R. Balpai, C. Xu, C. L. Kress, B. Bailly-Maitre, X. Li, A. Osterman, S. Matsuzawa, A. V. Terskikh, B. Faustin, and J. C. Reed. 2007. Bcl-2 and Bcl-XL regulate proinflammatory caspase-1 activation by interaction with NALP1. Cell 129: 45–56.
Ben-Neriah, Y., and M. Karin. 2011. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol 12: 715–723.
Wang, Y., X. Chen, W. Cao, and Y. Shi. 2014. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat Immunol 15: 1009–1016.
Lin, Y., L. Bai, W. Chen, and S. Xu. 2010. The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin Ther Targets 14: 45–55.
Yin, M. J., Y. Yamamoto, and R. B. Gaynor. 1998. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396: 77–80.
Veschini, L., D. Belloni, C. Foglieni, M. G. Cangi, M. Ferrarini, F. Caligaris-Cappio, and E. Ferrero. 2007. Hypoxia-inducible transcription factor-1 alpha determines sensitivity of endothelial cells to the proteosome inhibitor bortezomib. Blood 109: 2565–2570.
Jennings, C., B. Kusler, and P. P. Jones. 2009. Calcineurin inactivation leads to decreased responsiveness to LPS in macrophages and dendritic cells and protects against LPS-induced toxicity in vivo. Innate Immunol 15: 109–120.
Granelli-Piperno, A., P. Nolan, K. Inaba, and R. M. Steinman. 1990. The effect of immunosuppressive agents on the induction of nuclear factors that bind to sites on the interleukin 2 promoter. J Exp Med 172: 1869–1872.
Taniguchi, K., and M. Karin. 2018. NF-κ
B, inflammation, immunity and cancer: coming of age. Nat Rev Immunol 18: 309–324.
Kong, X., L. Li, Z. Li, and K. Xie. 2012. Targeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: molecular basis for therapeutic implications. Cytokine Growth Factor Rev 23: 343–356.
Sionov, R. V., Z. G. Fridlender, and Z. Granot. 2015. The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment. Cancer Microenviron 8: 125–158.
Bonavita, E., M. R. Galdiero, S. Jaillon, and A. Mantovani. 2015. Phagocytes as Corrupted Policemen in Cancer-Related Inflammation. Adv Cancer Res 128: 141–171.
Taniguchi, K., and M. Karin. 2018. NF-κ
B, inflammation, immunity and cancer: coming of age. Nature Rev Immunol 18: 309–324.
Joyce, D., C. Albanese, J. Steer, M. Fu, B. Bouzahzah, and R. G. Pestell. 2001. NF-kappaB and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev 12: 73–90.
Kiraly, O., G. Gong, W. Olipitz, S. Muthupalani, and B. P. Engelward. 2015. Inflammation-induced cell proliferation potentiates DNA damage-induced mutations in vivo. PLoS Genet 11: e1004901.
Shimizu, T., H. Marusawa, Y. Endo, and T. Chiba. 2012. Inflammation-mediated genomic instability: roles of activation-induced cytidine deaminase in carcinogenesis. Cancer Sci 103: 1201–1206.
Karin, M., and F. R. Greten. 2005. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5: 749–759.
Grivennikov, S. I., F. R. Greten, and M. Karin. 2010. Immunity, inflammation, and cancer. Cell 140: 883–899.
You, Z., L. V. Madrid, D. Saims, J. Sedivy, and C. Y. Wang. 2002. c-Myc sensitizes cells to tumor necrosis factor-mediated apoptosis by inhibiting nuclear factor kappa B transactivation. J Biol Chem 277: 36671–36677.
Pires, B. R., A. L. Mencalha, G. M. Ferreira, W. F. de Souza, J. A. Morgado-Díaz, A. M. Maia, S. Corrêa, and E. S. Abdelhay. 2017. NF-kappaB Is Involved in the Regulation of EMT Genes in Breast Cancer Cells. PLoS One 12: e0169622.
Wu, Y., and B. P. Zhou. 2009. Inflammation: a driving force speeds cancer metastasis. Cell Cycle 8: 3267–3273.
Gilkes, D. M., and G. L. Semenza. 2013. Role of hypoxia-inducible factors in breast cancer metastasis. Future Oncol 9: 1623–1636.
Spina, A., V. De Pasquale, G. Cerulo, P. Cocchiaro, R. Della Morte, L. Avallone, and L. M. Pavone. 2015. HGF/c-MET Axis in Tumor Microenvironment and Metastasis Formation. Biomedicines 3: 71–88.
Balkwill, F. 2004. Cancer and the chemokine network. Nat Rev Cancer 4: 540–550.
Vereecke, L., R. Beyaert, and G. van Loo. 2009. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol 30: 383–391.
Heyninck, K., D. De Valck, W. Vanden Berghe, W. Van Criekinge, R. Contreras, W. Fiers, G. Haegeman, and R. Beyaert. 1999. The zinc finger protein A20 inhibits TNF-induced NF-kappaB-dependent gene expression by interfering with an RIP- or TRAF2-mediated transactivation signal and directly binds to a novel NF-kappaB-inhibiting protein ABIN. J Cell Biol 145: 1471–1482.
Nakagawa, M. M., K. Thummar, J. Mandelbaum, L. Pasqualucci, and C. V. Rathinam. 2015. Lack of the ubiquitin-editing enzyme A20 results in loss of hematopoietic stem cell quiescence. J Exp Med 212: 203–216.
Sitcheran, R., P. C. Cogswell, and A. S. Baldwin, Jr. 2003. NF-kappaB mediates inhibition of mesenchymal cell differentiation through a posttranscriptional gene silencing mechanism. Genes Dev 17: 2368–2373.
Guttridge, D. C., M. W. Mayo, L. V. Madrid, C. Y. Wang, and A. S. Baldwin, Jr. 2000. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 289: 2363–2366.
Kaltschmidt, C., J. F. W. Greiner, and B. Kaltschmidt. 2021. The Transcription Factor NF-κ
B in Stem Cells and Development. Cells 10: 2042.
Chan, Y. H., Y. C. Lee, C. Y. Hung, P. J. Yang, P. C. Lai, and S. W. Feng. 2021. Three-dimensional Spheroid Culture Enhances Multipotent Differentiation and Stemness Capacities of Human Dental Pulp-derived Mesenchymal Stem Cells by Modulating MAPK and NF-kB Signaling Pathways. Stem Cell Rev Rep 17: 1810–1826.
Proto, J. D., A. Lu, A. Dorronsoro, A. Scibetta, P. D. Robbins, L. J. Niedernhofer, and J. Huard. 2017. Inhibition of NF-κ
B improves the stress resistance and myogenic differentiation of MDSPCs isolated from naturally aged mice. PLoS One 12: e0179270.
Greco, S. J., S. V. Smirnov, R. G. Murthy, and P. Rameshwar. 2007. Synergy between the RE-1 silencer of transcription and NFkappaB in the repression of the neurotransmitter gene TAC1 in human mesenchymal stem cells. J Biol Chem 282: 30039–30050.
Buhrmann, C., A. Mobasheri, U. Matis, and M. Shakibaei. 2010. Curcumin mediated suppression of nuclear factor-κ
B promotes chondrogenic differentiation of mesenchymal stem cells in a high-density co-culture microenvironment. Arthritis Res Ther 12: R127.
Langen, R. C., A. M. Schols, M. C. Kelders, E. F. Wouters, and Y. M. Janssen-Heininger. 2001. Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor-kappaB. FASEB J 15: 1169–1180.
Hess, K., A. Ushmorov, J. Fiedler, R. E. Brenner, and T. Wirth. 2009. TNFalpha promotes osteogenic differentiation of human mesenchymal stem cells by triggering the NF-kappaB signaling pathway. Bone 45: 367–376.
Lu, Z., G. Wang, C. R. Dunstan, and H. Zreiqat. 2012. Short-term exposure to tumor necrosis factor-alpha enables human osteoblasts to direct adipose tissue-derived mesenchymal stem cells into osteogenic differentiation. Stem Cells Dev 21: 2420–2429.
Lombardo, E., O. DelaRosa, P. Mancheño-Corvo, R. Menta, C. Ramírez, and D. Büscher. 2009. Toll-like receptor-mediated signaling in human adipose-derived stem cells: implications for immunogenicity and immunosuppressive potential. Tissue Eng Part A 15: 1579–1589.
Vazquez-Santillan, K., J. Melendez-Zajgla, L. Jimenez-Hernandez, G. Martínez-Ruiz, and V. Maldonado. 2015. NF-κ
B signaling in cancer stem cells: a promising therapeutic target? Cell Oncol (Dordr) 38: 327–339.
Shigdar, S., Y. Li, S. Bhattacharya, M. O’Connor, C. Pu, J. Lin, T. Wang, D. Xiang, L. Kong, M. Q. Wei, Y. Zhu, S. Zhou, and W. Duan. 2014. Inflammation and cancer stem cells. Cancer Lett 345: 271–278.
Rinkenbaugh, A. L., and A. S. Baldwin. 2016. The NF-κ
B Pathway and Cancer Stem Cells. Cells 5.
Wendt, M. K., N. Balanis, C. R. Carlin, and W. P. Schiemann. 2014. STAT3 and epithelial-mesenchymal transitions in carcinomas. Jakstat 3: e28975.
Yamamoto, M., Y. Taguchi, T. Ito-Kureha, K. Semba, N. Yamaguchi, and J. Inoue. 2013. NF-κ
B non-cell-autonomously regulates cancer stem cell populations in the basal-like breast cancer subtype. Nat Commun 4: 2299.
Guzman, M. L., S. J. Neering, D. Upchurch, B. Grimes, D. S. Howard, D. A. Rizzieri, S. M. Luger, and C. T. Jordan. 2001. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 98: 2301–2307.
Mitsiades, C. S., N. Mitsiades, V. Poulaki, R. Schlossman, M. Akiyama, D. Chauhan, T. Hideshima, S. P. Treon, N. C. Munshi, P. G. Richardson, and K. C. Anderson. 2002. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 21: 5673–5683.
Zhou, J., J. Y. Chooi, Y. Q. Ching, J. Y. Quah, S. H. Toh, Y. Ng, T. Z. Tan, and W. J. Chng. 2018. NF-κ
B promotes the stem-like properties of leukemia cells by activation of LIN28B. World J Stem Cells 10: 34–42.
Gallipoli, P., F. Pellicano, H. Morrison, K. Laidlaw, E. K. Allan, R. Bhatia, M. Copland, H. G. Jørgensen, and T. L. Holyoake. 2013. Autocrine TNF-α
production supports CML stem and progenitor cell survival and enhances their proliferation. Blood 122: 3335–3339.
Chefetz, I., A. B. Alvero, J. C. Holmberg, N. Lebowitz, V. Craveiro, Y. Yang-Hartwich, G. Yin, L. Squillace, M. Gurrea Soteras, P. Aldo, and G. Mor. 2013. TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence. Cell Cycle 12: 511–521.
Burnstock, G. 2018. Purine and purinergic receptors. Brain Neurosci Adv 2: 2398212818817494.
Haskó, G., and B. Cronstein. 2013. Regulation of inflammation by adenosine. Front Immunol 4: 85.
North, R. A. 2002. Molecular physiology of P2X receptors. Physiol Rev 82: 1013–1067.
Burnstock, G., and G. E. Knight. 2004. Cellular distribution and functions of P2 receptor subtypes in different systems. Int Rev Cytol 240: 31–304.
Burnstock, G. 2006. Pathophysiology and therapeutic potential of purinergic signaling. Pharmacol Rev 58: 58–86.
Verkhratsky, A., and G. Burnstock. 2014. Biology of purinergic signalling: its ancient evolutionary roots, its omnipresence and its multiple functional significance. Bioessays 36: 697–705.
Vadlamani, V. M. K., K. K. J. Gunasinghe, X. W. Chee, T. Rahman, and M. T. Harper. 2023. Human soluble CD39 displays substrate inhibition in a substrate-specific manner. Sci Rep 13: 8958.
Giuliani, A. L., A. C. Sarti, and F. Di Virgilio. 2020. Ectonucleotidases in Acute and Chronic Inflammation. Front Pharmacol 11: 619458.
Allard, B., M. S. Longhi, S. C. Robson, and J. Stagg. 2017. The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets. Immunol Rev 276: 121–144.
Burnstock, G., and C. Kennedy. 1985. Is there a basis for distinguishing two types of P2-purinoceptor? Gen Pharmacol 16: 433–440.
Fredholm, B. B., I. J. AP, K. A. Jacobson, K. N. Klotz, and J. Linden. 2001. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53: 527–552.
Abbracchio, M. P., and G. Burnstock. 1994. Purinoceptors: are there families of P2X and P2Y purinoceptors? Pharmacol Ther 64: 445–475.
Huang, Z., N. Xie, P. Illes, F. Di Virgilio, H. Ulrich, A. Semyanov, A. Verkhratsky, B. Sperlagh, S. G. Yu, C. Huang, and Y. Tang. 2021. From purines to purinergic signalling: molecular functions and human diseases. Signal Transduct Target Ther 6: 162.
Duarte-Silva, E., H. Ulrich, Á. Oliveira-Giacomelli, H. P. Hartung, S. G. Meuth, and C. A. Peixoto. 2022. The adenosinergic signaling in the pathogenesis and treatment of multiple sclerosis. Front Immunol 13: 946698.
Passarella, D., M. Ronci, V. Di Liberto, M. Zuccarini, G. Mudò, C. Porcile, M. Frinchi, P. Di Iorio, H. Ulrich, and C. Russo. 2022. Bidirectional Control between Cholesterol Shuttle and Purine Signal at the Central Nervous System. Int J Mol Sci 23.
Tomczyk, M., T. Glaser, E. M. Slominska, H. Ulrich, and R. T. Smolenski. 2021. Purine Nucleotides Metabolism and Signaling in Huntington’s Disease: Search for a Target for Novel Therapies. Int J Mol Sci 22: 6545.
Li, Y., X. Han, J. Tong, Y. Wang, X. Liu, Z. Liao, M. Jiang, and H. Zhao. 2023. Analysis of Metabolites in Gout: A Systematic Review and Meta-Analysis. Nutrients 15: 3143.
Gilbert, S. M., C. J. Oliphant, S. Hassan, A. L. Peille, P. Bronsert, S. Falzoni, F. Di Virgilio, S. McNulty, and R. Lara. 2019. ATP in the tumour microenvironment drives expression of nfP2X(7), a key mediator of cancer cell survival. Oncogene 38: 194–208.
Burnstock, G., and F. Di Virgilio. 2013. Purinergic signalling and cancer. Purinergic Signal 9: 491–540.
Jia, W., Z. Huang, L. Zhou, Y. C. Liou, F. Di Virgilio, H. Ulrich, P. Illes, W. Zhang, C. Huang, and Y. Tang. 2023. Purinergic signalling in cancer therapeutic resistance: From mechanisms to targeting strategies. Drug Resist Updat 70: 100988.
He, J. R., S. G. Yu, Y. Tang, and P. Illes. 2020. Purinergic signaling as a basis of acupuncture-induced analgesia. Purinergic Signal 16: 297–304.
Deaglio, S., K. M. Dwyer, W. Gao, D. Friedman, A. Usheva, A. Erat, J. F. Chen, K. Enjyoji, J. Linden, M. Oukka, V. K. Kuchroo, T. B. Strom, and S. C. Robson. 2007. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 204: 1257–1265.
Linden, J., F. Koch-Nolte, and G. Dahl. 2019. Purine Release, Metabolism, and Signaling in the Inflammatory Response. Annu Rev Immunol 37: 325–347.
Bissacotti, B. F., P. M. Copetti, N. B. Bottari, T. V. Palma, M. M. Pillat, C. M. de Andrade, V. M. M. Morsch, H. Ulrich, and A. S. da Silva. 2023. Curcumin modulates neurogliogenesis and purinergic receptor expression in neural precursor cells infected with Toxoplasma gondii. Parasitol Res 122: 77–84.
Franczak, S., H. Ulrich, and M. Z. Ratajczak. 2025. Hematopoietic stem cells on the crossroad between purinergic signaling and innate immunity. Purinergic Signal 21: 3–9.
Ratajczak, M. Z., M. Adamiak, K. Bujko, A. Thapa, V. Pensato, M. Kucia, J. Ratajczak, and H. Ulrich. 2020. Innate immunity orchestrates the mobilization and homing of hematopoietic stem/progenitor cells by engaging purinergic signaling-an update. Purinergic Signal 16: 153–166.
Sheth, S., R. Brito, D. Mukherjea, L. P. Rybak, and V. Ramkumar. 2014. Adenosine receptors: expression, function and regulation. Int J Mol Sci 15: 2024–2052.
Bertolini, G., M. Compagno, D. C. Belisario, C. Bracci, T. Genova, F. Mussano, M. Vitale, A. Horenstein, F. Malavasi, R. Ferracini, and I. Roato. 2022. CD73/Adenosine Pathway Involvement in the Interaction of Non-Small Cell Lung Cancer Stem Cells and Bone Cells in the Pre-Metastatic Niche. Int J Mol Sci 23.
Liu, R., W. Chang, H. Wei, and K. Zhang. 2016. Comparison of the Biological Characteristics of Mesenchymal Stem Cells Derived from Bone Marrow and Skin. Stem Cells Int 2016: 3658798.
Torres, A., Y. Vargas, D. Uribe, C. Jaramillo, A. Gleisner, F. Salazar-Onfray, M. N. López, R. Melo, C. Oyarzún, R. San Martín, and C. Quezada. 2016. Adenosine A3 receptor elicits chemoresistance mediated by multiple resistance-associated protein-1 in human glioblastoma stem-like cells. Oncotarget 7: 67373–67386.
Uhlén, M., L. Fagerberg, B. M. Hallström, C. Lindskog, P. Oksvold, A. Mardinoglu, Å. Sivertsson, C. Kampf, E. Sjöstedt, A. Asplund, I. Olsson, K. Edlund, E. Lundberg, S. Navani, C. A. Szigyarto, J. Odeberg, D. Djureinovic, J. O. Takanen, S. Hober, T. Alm, P. H. Edqvist, H. Berling, H. Tegel, J. Mulder, J. Rockberg, P. Nilsson, J. M. Schwenk, M. Hamsten, K. von Feilitzen, M. Forsberg, L. Persson, F. Johansson, M. Zwahlen, G. von Heijne, J. Nielsen, and F. Pontén. 2015. Proteomics. Tissue-based map of the human proteome. Science 347: 1260419.
Sattler, C., M. Steinsdoerfer, M. Offers, E. Fischer, R. Schierl, K. Heseler, W. Däubener, and J. Seissler. 2011. Inhibition of T-cell proliferation by murine multipotent mesenchymal stromal cells is mediated by CD39 expression and adenosine generation. Cell Transplant 20: 1221–1230.
Eltzschig, H. K., J. C. Ibla, G. T. Furuta, M. O. Leonard, K. A. Jacobson, K. Enjyoji, S. C. Robson, and S. P. Colgan. 2003. Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. J Exp Med 198: 783–796.
Kaebisch, C., D. Schipper, P. Babczyk, and E. Tobiasch. 2015. The role of purinergic receptors in stem cell differentiation. Comput Struct Biotechnol J 13: 75–84.
Carroll, S. H., N. A. Wigner, N. Kulkarni, H. Johnston-Cox, L. C. Gerstenfeld, and K. Ravid. 2012. A2B adenosine receptor promotes mesenchymal stem cell differentiation to osteoblasts and bone formation in vivo. J Biol Chem 287: 15718–15727.
He, W., A. Mazumder, T. Wilder, and B. N. Cronstein. 2013. Adenosine regulates bone metabolism via A1, A2A, and A2B receptors in bone marrow cells from normal humans and patients with multiple myeloma. FASEB J 27: 3446–3454.
Shih, Y. R., Y. Hwang, A. Phadke, H. Kang, N. S. Hwang, E. J. Caro, S. Nguyen, M. Siu, E. A. Theodorakis, N. C. Gianneschi, K. S. Vecchio, S. Chien, O. K. Lee, and S. Varghese. 2014. Calcium phosphate-bearing matrices induce osteogenic differentiation of stem cells through adenosine signaling. Proc Natl Acad Sci U S A 111: 990–995.
Gharibi, B., A. A. Abraham, J. Ham, and B. A. Evans. 2012. Contrasting effects of A1 and A2b adenosine receptors on adipogenesis. Int J Obes (Lond) 36: 397–406.
Soliman, H., M. Theret, W. Scott, L. Hill, T. M. Underhill, B. Hinz, and F. M. V. Rossi. 2021. Multipotent stromal cells: One name, multiple identities. Cell Stem Cell 28: 1690–1707.
Patel, N., T. E. Klassert, S. J. Greco, S. A. Patel, J. L. Munoz, B. Y. Reddy, M. Bryan, N. Campbell, N. Kokorina, H. E. Sabaawy, and P. Rameshwar. 2012. Developmental regulation of TAC1 in peptidergic-induced human mesenchymal stem cells: implication for spinal cord injury in zebrafish. Stem Cells Dev 21: 308–320.
da Silva Meirelles, L., A. I. Caplan, and N. B. Nardi. 2008. In search of the in vivo identity of mesenchymal stem cells. Stem Cells 26: 2287–2299.
Kusiak, A., and G. Brady. 2022. Bifurcation of signalling in human innate immune pathways to NF-kB and IRF family activation. Biochem Pharmacol 205: 115246.
Zinatizadeh, M. R., B. Schock, G. M. Chalbatani, P. K. Zarandi, S. A. Jalali, and S. R. Miri. 2021. The Nuclear Factor Kappa B (NF-kB) signaling in cancer development and immune diseases. Genes Dis 8: 287–297.
Li, Y., X. Wang, and J. Lu. 2023. Interleukin-35 Promote Osteogenesis and Inhibit Adipogenesis: Role of Wnt/β
-Catenin and PPARγ
Signaling Pathways. Inflammation 46: 522–533.
Das, R., J. Giri, K. P. P, N. Froelich, R. Chinnadurai, S. McCoy, W. Bushman, and J. Galipeau. 2022. A STAT5-Smad3 dyad regulates adipogenic plasticity of visceral adipose mesenchymal stromal cells during chronic inflammation. Regen Med 7: 41.
Zhang, Y., L. Ling, D. O. A. A. Ajay, Y. M. Eio, A. J. van Wijnen, V. Nurcombe, and S. M. Cool. 2022. FGFR2 accommodates osteogenic cell fate determination in human mesenchymal stem cells. Gene 818: 146199.
Yoon, D. S., Y. H. Kim, S. Lee, K. M. Lee, K. H. Park, Y. Jang, and J. W. Lee. 2014. Interleukin-6 induces the lineage commitment of bone marrow-derived mesenchymal multipotent cells through down-regulation of Sox2 by osteogenic transcription factors. FASEB J 28: 3273–3286.
Iwata, T., N. Mizuno, T. Nagahara, E. Kaneda-Ikeda, M. Kajiya, S. Sasaki, K. Takeda, M. Kiyota, R. Yagi, T. Fujita, and H. Kurihara. 2022. Cytokines regulate stemness of mesenchymal stem cells via miR-628–5p during periodontal regeneration. J Periodontol 93: 269–286.
Gu, Y., X. Ding, J. Huang, M. Xue, J. Zhang, Q. Wang, H. Yu, Y. Wang, F. Zhao, H. Wang, M. Jin, Y. Wu, and Y. Zhang. 2018. The deubiquitinating enzyme UCHL1 negatively regulates the immunosuppressive capacity and survival of multipotent mesenchymal stromal cells. Cell Death Dis 9: 459.
Yuan, X., D. Ferrari, T. Mills, Y. Wang, A. Czopik, M. F. Doursout, S. E. Evans, M. Idzko, and H. K. Eltzschig. 2021. Editorial: Purinergic Signaling and Inflammation. Front Immunol 12: 699069.
Rossi, L., V. Salvestrini, D. Ferrari, F. Di Virgilio, and R. M. Lemoli. 2012. The sixth sense: hematopoietic stem cells detect danger through purinergic signaling. Blood 120: 2365–2375.
Scarfì, S. 2014. Purinergic receptors and nucleotide processing ectoenzymes: Their roles in regulating mesenchymal stem cell functions. World J Stem Cells 6: 153–162.
Sun, Y., W. Hu, X. Yu, Z. Liu, R. Tarran, K. Ravid, and P. Huang. 2016. Actinin-1 binds to the C-terminus of A2B adenosine receptor (A2BAR) and enhances A2BAR cell-surface expression. Biochem J 473: 2179–2186.
Zhao, N., G. Xia, J. Cai, Z. Li, and X. W. Lv. 2022. Adenosine receptor A2B mediates alcoholic hepatitis by regulating cAMP levels and the NF-KB pathway. Toxicol Lett 359: 84–95.
Murphy, P. S., J. Wang, S. P. Bhagwat, J. C. Munger, W. J. Janssen, T. W. Wright, and M. R. Elliott. 2017. CD73 regulates anti-inflammatory signaling between apoptotic cells and endotoxin-conditioned tissue macrophages. Cell Death Differ 24: 559–570.
Bauer, F. N., T. Tertel, O. Stambouli, C. Wang, R. Dittrich, S. Staubach, V. Börger, D. M. Hermann, S. Brandau, and B. Giebel. 2023. CD73 activity of mesenchymal stromal cell-derived extracellular vesicle preparations is detergent-resistant and does not correlate with immunomodulatory capabilities. Cytotherapy 25: 138–147.
Burand, A. J., Jr., L. Di, L. K. Boland, D. T. Boyt, M. V. Schrodt, D. A. Santillan, and J. A. Ankrum. 2020. Aggregation of Human Mesenchymal Stromal Cells Eliminates Their Ability to Suppress Human T Cells. Front Immunol 11: 143.
Grünewald, J. K., and A. J. Ridley. 2010. CD73 represses pro-inflammatory responses in human endothelial cells. J Inflamm (Lond) 7: 10.
Tan, K., H. Zhu, J. Zhang, W. Ouyang, J. Tang, Y. Zhang, L. Qiu, X. Liu, Z. Ding, and X. Deng. 2019. CD73 Expression on Mesenchymal Stem Cells Dictates the Reparative Properties via Its Anti-Inflammatory Activity. Stem Cells Int 2019: 8717694.
Yang, J., X. Liao, J. Yu, and P. Zhou. 2018. Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target. Curr Med Chem 25: 2260–2271.
Ramos, T. L., L. I. Sánchez-Abarca, B. Rosón-Burgo, A. Redondo, A. Rico, S. Preciado, R. Ortega, C. Rodríguez, S. Muntión, Á. Hernández-Hernández, J. De Las Rivas, M. González, J. R. González Porras, C. Del Cañizo, and F. Sánchez-Guijo. 2017. Mesenchymal stromal cells (MSC) from JAK2+ myeloproliferative neoplasms differ from normal MSC and contribute to the maintenance of neoplastic hematopoiesis. PLoS One 12: e0182470.
